Collegium Pharmaceutical, Inc. (COLL)
24.75
+0.54
(+2.23%)
USD |
NASDAQ |
Nov 09, 10:09
Collegium Pharmaceutical Shareholders Equity (Quarterly) : 296.44M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 296.44M |
| June 30, 2026 | 311.91M |
| March 31, 2026 | 312.42M |
| December 31, 2025 | 301.68M |
| September 30, 2025 | 274.81M |
| June 30, 2025 | 232.21M |
| March 31, 2025 | 234.43M |
| December 31, 2024 | 228.84M |
| September 30, 2024 | 234.28M |
| June 30, 2024 | 216.58M |
| March 31, 2024 | 222.17M |
| December 31, 2023 | 195.43M |
| September 30, 2023 | 178.87M |
| June 30, 2023 | 200.80M |
| March 31, 2023 | 179.73M |
| December 31, 2022 | 194.84M |
| September 30, 2022 | 197.19M |
| June 30, 2022 | 197.61M |
| March 31, 2022 | 196.08M |
| December 31, 2021 | 202.93M |
| September 30, 2021 | 251.09M |
| June 30, 2021 | 253.07M |
| March 31, 2021 | 170.04M |
| December 31, 2020 | 186.03M |
| Date | Value |
|---|---|
| September 30, 2020 | 172.69M |
| June 30, 2020 | 155.77M |
| March 31, 2020 | 141.06M |
| December 31, 2019 | 87.43M |
| September 30, 2019 | 84.26M |
| June 30, 2019 | 85.82M |
| March 31, 2019 | 86.35M |
| December 31, 2018 | 91.58M |
| September 30, 2018 | 70.78M |
| June 30, 2018 | 82.68M |
| March 31, 2018 | 90.82M |
| December 31, 2017 | 104.08M |
| September 30, 2017 | 96.27M |
| June 30, 2017 | 95.51M |
| March 31, 2017 | 114.37M |
| December 31, 2016 | 134.91M |
| September 30, 2016 | 74.32M |
| June 30, 2016 | 98.66M |
| March 31, 2016 | 121.74M |
| December 31, 2015 | 85.07M |
| September 30, 2015 | 93.56M |
| June 30, 2015 | 102.42M |
| March 31, 2015 | 34.45M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 637.11M |
| Corcept Therapeutics, Inc. | 833.74M |
| Veru, Inc. | 28.38M |
| Johnson & Johnson | 81.53B |
| Eli Lilly & Co. | 40.27B |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.096B |
| Total Liabilities (Quarterly) | 1.799B |
| Debt to Equity Ratio | 4.074 |
| Current Ratio | 1.014 |
| Net Debt Paydown Yield | -7.55% |